Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

PD-1 Inhibitors Demonstrate Promise as Salvage Therapy in R/R Extranodal NK/T-cell Lymphoma

July 31st 2023

Amira Marouf, MD, PhD student, describes the nature of a comparative analysis conducted based on propensity score matching, and discussed the main takeaways regarding the efficacy of PD-1 inhibitors for patients with relapsed/refractory ENKTCL.

Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023

July 31st 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

July 31st 2023

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Dr Bewersdorf on Ruxolitinib Plus Abemaciclib in Myelofibrosis

July 28th 2023

Jan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

July 28th 2023

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

July 28th 2023

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

BMF-219 Demonstrates Early Activity in Menin-Dependent AML

July 25th 2023

Oral treatment with BMF-219 led to 2 complete responses of 5 patients with relapsed/refractory acute myeloid leukemia with menin-dependent mutations, both of which remain on treatment.

Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS

July 25th 2023

The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued due to futility at a planned analysis.

Optimizing MF Management With Multidisciplinary Care

July 25th 2023

A comprehensive discussion on the members of a healthcare team who might help to diagnose and manage a patient with myelofibrosis.

Molecular Markers and Subsets of Myelofibrosis

July 25th 2023

Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.

Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

July 24th 2023

Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.

Axatilimab Meets ORR End Point in Chronic GVHD After 2 or More Prior Lines of Therapy

July 24th 2023

The anti–CSF-R1 antibody axatilimab generated responses in adult and pediatric patients with chronic graft-vs-host disease who received 2 or more prior lines of therapy, meeting the primary end point in all cohorts of patients in the phase 2 AGAVE-201 trial.

FDA Approves Companion Diagnostic for Quizartinib in FLT3-ITD+ AML

July 24th 2023

The FDA has approved the LeukoStrat CDx FLT3 Mutation Assay for use as a companion diagnostic to select patients with FLT3-ITD–positive acute myeloid leukemia who may be eligible to receive treatment with quizartinib (Vanflyta).1

Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

JZP458 Receives CHMP Recommendation for Approval in ALL, Lymphoblastic Lymphoma

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of JZP458 for use in combination with multi-agent chemotherapy for the treatment of adult and pediatric patients 1 month and older with acute lymphoblastic leukemia and lymphoblastic lymphoma who developed hypersensitivity or silent inactivation to Escherichia coli–derived asparaginase.

Dr Falchi on the Use of Glofitamab in R/R LBCL

July 21st 2023

Lorenzo Falchi, MD, iscusses the use of glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Dr Erba on the FDA Approval of Quizartinib Plus Chemotherapy in FLT3-ITD–Positive AML

July 20th 2023

Harry P. Erba, MD, PhD, discusses the significance of the FDA approval of quizartinib in combination with chemotherapy in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

FDA Approves Quizartinib Plus Chemotherapy for Newly Diagnosed, FLT3-ITD+ AML

July 20th 2023

The FDA has approved quizartinib in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive, as detected by an FDA-approved test.

APVO436 Plus Venetoclax/Azacitidine Produces Durable Remissions in Relapsed/Refractory AML

July 20th 2023

Treatment with the CD3 x CD123 bispecific antibody APVO436 plus venetoclax and azacitidine led to durable remissions in patients with relapsed/refractory acute myeloid leukemia who had not received prior venetoclax.